| 2025-11-26 |
详情>>
内部人交易：
Noznesky Justin J股份减少5166.00股
|
| 2025-10-30 |
详情>>
股本变动：
变动后总股本4971.70万股
|
| 2025-10-30 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.28美元,归母净利润-1320.4万美元,同比去年增长54.67%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-07-30 |
详情>>
业绩披露：
2025年中报每股收益-0.27美元,归母净利润-1293.7万美元,同比去年增长39.20%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.14美元,归母净利润-674.7万美元,同比去年增长49.15%
|
| 2025-04-07 |
股东大会：
将于2025-05-19召开股东大会
会议内容 ▼▲
- 1.To elect nine directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,700,000;
4.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
5.To conduct an advisory vote on the frequency of future advisory votes on compensation of our named executive officers;
6.To transact such other business as may properly come before the Annual Meeting or any continuations, postponements or adjournments by or at the discretion of the Board of Directors of the Company.
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益-0.95美元,归母净利润-4469.8万美元,同比去年增长-46.85%
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益-1.02美元,归母净利润-4646.6万美元,同比去年增长-192.56%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.62美元,归母净利润-2913万美元,同比去年增长-41.07%
|
| 2024-07-31 |
详情>>
业绩披露：
2023年中报每股收益-0.25美元,归母净利润-1159.4万美元,同比去年增长61.38%
|
| 2024-07-31 |
详情>>
业绩披露：
2024年中报每股收益-0.45美元,归母净利润-2127.7万美元,同比去年增长-83.52%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.28美元,归母净利润-1326.9万美元,同比去年增长-104.89%
|
| 2024-04-03 |
股东大会：
将于2024-05-13召开股东大会
会议内容 ▼▲
- 1.To elect nine directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2025 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
4.To approve an amendment to the AtriCure, Inc. 2023 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,800,000;
5.To approve an amendment to AtriCure's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company;
6.To transact such other business as may properly come before the Annual Meeting or any continuations, postponements or adjournments by or at the discretion of the Board of Directors of the Company.
|
| 2024-02-16 |
详情>>
业绩披露：
2023年年报每股收益-0.66美元,归母净利润-3043.8万美元,同比去年增长34.49%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.45美元,归母净利润-2064.9万美元,同比去年增长51.18%
|
| 2023-04-10 |
股东大会：
将于2023-05-25召开股东大会
会议内容 ▼▲
- 1.To elect eight directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2024 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve the AtriCure, Inc. 2023 Stock Incentive Plan;
4.To approve an amendment to the AtriCure, Inc. 2018 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance thereunder by 750,000;
5.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
6.To transact such other business as may properly come before the Annual Meeting or any continuations, postponements or adjournments.
|
| 2022-04-11 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect nine directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2023 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 1,100,000;
4.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
5.To transact such other business as may properly come before the Annual Meeting or any continuations, postponements or adjournments.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-08 |
股东大会：
将于2021-05-20召开股东大会
会议内容 ▼▲
- 1.To elect eight directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2022 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
4.To transact such other business as may properly come before the Annual Meeting or any continuations, postponements or adjournments.
|
| 2020-04-08 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.To elect ten directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2021 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 900,000;
4.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
5.To transact such other business as may properly come before the Annual Meeting or any postponements or adjournments.
|
| 2019-04-10 |
股东大会：
将于2019-05-22召开股东大会
会议内容 ▼▲
- 1.To elect eight directors nominated by the Board of Directors, each to serve for a one-year term that expires at the 2020 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 900,000;
4.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
5.To conduct an advisory vote on the frequency of future advisory votes on compensation of our named executive officers;
6.To transact such other business as may properly come before the Annual Meeting or any postponements or adjournments.
|
| 2018-04-10 |
股东大会：
将于2018-05-22召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to serve for a one-year term that expires at the 2019 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
4.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 850,000 and amend the provisions relating to equity awards payable to non-employee directors;
5.To approve the AtriCure, Inc. 2018 Employee Stock Purchase Plan;
6.To transact such other business as may properly come before the Annual Meeting or any postponements or adjournments of the Annual Meeting.
|
| 2017-04-12 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1.To elect ten directors to serve for a one-year term that expires at the 2018 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
4.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 850,000 shares and change the terms of non-employee director equity grants;
5.To transact such other business as may properly come before the Annual Meeting.
|
| 2016-03-31 |
股东大会：
将于2016-05-25召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve for a one-year term that expires at the 2017 Annual Meeting of Stockholders and until their successors have been duly elected and qualified;
2.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2016;
3.To conduct an advisory vote on the compensation of our named executive officers as disclosed in this proxy statement;
4.To approve and adopt an amendment to AtriCure’s Certificate of Incorporation;
5.To approve an amendment to the AtriCure, Inc. 2014 Stock Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 450,000 shares and re-approve its performance measures for purposes of Section 162(m) of the Internal Revenue Code;
6.To transact such other business as may properly come before the Annual Meeting.
|